# Promoting Repigmentation After Epidermal Cell Suspension Grafting and preVENTing the Loss of Melanocytes Using Topical Ruxolitinib for Vitiligo in Resistant Areas

> **NCT05872477** · PHASE2 · COMPLETED · sponsor: **Centre Hospitalier Universitaire de Nice** · enrollment: 20 (actual)

## Conditions studied

- Vitiligo

## Interventions

- **DRUG:** Ruxolitinib Topical
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05872477
- **Lead sponsor:** Centre Hospitalier Universitaire de Nice
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-09-05
- **Primary completion:** 2024-02-08
- **Final completion:** 2025-01-10
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2025-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05872477

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05872477, "Promoting Repigmentation After Epidermal Cell Suspension Grafting and preVENTing the Loss of Melanocytes Using Topical Ruxolitinib for Vitiligo in Resistant Areas". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT05872477. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*